12:00 AM
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LDK378: Additional Phase I data

Additional data from 114 evaluable patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) in an open-label, dose-escalation, international Phase I trial showed that once-daily oral 400-750 mg LDK378 led to an ORR of 58%, including 1 complete response and 65 partial responses. Median duration of response was 8.2 months and median progression-free...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >